Subtype
Extranodal NK-/T-Cell Lymphoma, Nasal Type
CI-CAN-00009487Explore in graph →
Hematologic2 active trials
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00009487Explore in graph →
Clinical trials
23 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (4)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04414163 | A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type | active not recruiting | Phase 2 | 23 | ImmuneOncia Therapeutics Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05475925 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | recruiting | Phase 1 / Phase 2 | 200 | Dren BioINDUSTRY | 9 | Jun 17, 2026 | clinicaltrials |
| NCT05978141 |
| A Registry for People With T-cell Lymphoma |
| recruiting |
| — |
| 1,000 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| May 20, 2026 |
| clinicaltrials |
| NCT03493451 | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms | completed | Phase 2 | 77 | BeiGeneINDUSTRY | 5 | Oct 26, 2024 | clinicaltrials |
| NCT04509466 | Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL | terminated | Phase 1 / Phase 2 | 41 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT04602065 | Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial | terminated | Phase 1 / Phase 2 | 9 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT04639843 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02733458 | GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma | completed | N/A | 52 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT03079544 | Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients | completed | — | 665 | Rong TaoOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT02631239 | MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma | unknown | Phase 3 | 256 | Ruijin HospitalOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04676789 | Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL(SPENT) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT03363555 | SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma | unknown | Phase 2 | 97 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 18, 2020 | clinicaltrials |
| NCT04405375 | GPED Regimen for Relapsed/Refractory or Advanced ENKTCL | unknown | Phase 2 | 29 | Beijing Tongren HospitalOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT02764281 | MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma | completed | N/A | 53 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 27, 2020 | clinicaltrials |
| NCT04338282 | Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma | unknown | Phase 2 | 20 | Beijing Tongren HospitalOTHER | 0 | Apr 8, 2020 | clinicaltrials |
| NCT02386813 | International Extranodal NK/T-cell Lymphoma Project(PINK) | completed | — | 770 | Samsung Medical CenterOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT01991158 | GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jun 14, 2016 | clinicaltrials |
| NCT02229682 | Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Sep 30, 2014 | clinicaltrials |
| NCT00901147 | Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma | completed | Phase 2 | 25 | Singapore General HospitalOTHER | 3 | Jun 27, 2014 | clinicaltrials |
| NCT01921790 | Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Aug 22, 2013 | clinicaltrials |
| NCT01667289 | Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma | terminated | Phase 2 | 4 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT01667302 | Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials